skip to main content

Dyslipidaemia — EECC MCQ

Instant feedback + full explanation. One question, done properly.

HardHypertension & Preventive CardiologyDyslipidaemiaEECC

A 66-year-old man with a history of NSTEMI 18 months ago is seen for secondary prevention review. He is on aspirin 75 mg, atorvastatin 80 mg, ramipril 10 mg, and bisoprolol 2.5 mg. His LDL-cholesterol is 2.1 mmol/L. He has no diabetes. eGFR is 65 mL/min/1.73 m2. Per the ESC/EAS 2019 Guidelines (with 2025 Focused Update), what LDL-cholesterol target applies to this patient?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Less than 1.4 mmol/L and at least a 50% reduction from baseline

A previous NSTEMI is documented atherosclerotic cardiovascular disease, so this is secondary prevention and the patient is automatically in the ESC/EAS very-high cardiovascular risk category. For very-high-risk patients, the ESC/EAS LDL-cholesterol goal is both an absolute LDL-C below 1.4 mmol/L and at least a 50% reduction from baseline. His current LDL-C of 2.1 mmol/L is therefore above the ESC/EAS target. The <1.0 mmol/L target is only considered for selected patients with a second vascular event within 2 years despite maximally tolerated statin-based therapy, which is not described here.

Reference: European Society of Cardiology/European Atherosclerosis Society. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal, 2025. https://academic.oup.com/eurheartj/article/46/42/4359/8234482